Lebrikizumab in Moderate-to-severe Atopic Dermatitis
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
Active, not recruiting · NCT06906497 · Registry updated 2026-09-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Lebrikizumab in Moderate-to-severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Phase 4 | 2026-09-15 | NCT06906497 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Almirall, S.A. | 15 |
| Dermira, Inc. | 2 |
| Johann E Gudjonsson MD PhD | 1 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Lausanne University Hospital | Lausanne | Switzerland | 1 |
| Physioseq USA - CA | Folsom | United States | 1 |
| University of Freiburg | Freiburg im Breisgau | Germany | 1 |
| University of Michigan | Ann Arbor | United States | 538 |